FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2778889768> ?p ?o ?g. }

• W2778889768 endingPage "5232" @default.
• W2778889768 startingPage "5216" @default.
• W2778889768 abstract "Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of which focus on the cell signaling mechanisms controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a number of cancers, most recently as an oncogene in colorectal cancers. Our lab synthesized and characterized CP668863 - now called 20-223. In our established colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series of cell-free and cell-based studies to understand the mechanism of its anti-tumor effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 was ∼3.5-fold and ∼65.3-fold more potent than known clinically used CDK inhibitor, AT7519, respectively. Cell-based studies examining phosphorylation of downstream substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and was on an average >2-fold more potent than AT7519. Cell cycle analyses in CRC cells revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a suitable lead compound for colorectal cancer therapy." @default.
• W2778889768 created "2018-01-05" @default.
• W2778889768 creator A5005727339 @default.
• W2778889768 creator A5012581623 @default.
• W2778889768 creator A5022710064 @default.
• W2778889768 creator A5024236106 @default.
• W2778889768 creator A5026061991 @default.
• W2778889768 creator A5033239597 @default.
• W2778889768 creator A5037677450 @default.
• W2778889768 creator A5039080856 @default.
• W2778889768 creator A5041348263 @default.
• W2778889768 creator A5045971373 @default.
• W2778889768 creator A5051013360 @default.
• W2778889768 creator A5055721473 @default.
• W2778889768 creator A5055734394 @default.
• W2778889768 creator A5068782440 @default.
• W2778889768 creator A5077006529 @default.
• W2778889768 creator A5085882685 @default.
• W2778889768 creator A5086098906 @default.
• W2778889768 date "2017-12-28" @default.
• W2778889768 modified "2023-10-12" @default.
• W2778889768 title "Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy" @default.
• W2778889768 cites W1814857925 @default.
• W2778889768 cites W1833170350 @default.
• W2778889768 cites W1975972702 @default.
• W2778889768 cites W1982308040 @default.
• W2778889768 cites W1983988675 @default.
• W2778889768 cites W1998071315 @default.
• W2778889768 cites W2015728503 @default.
• W2778889768 cites W2016887265 @default.
• W2778889768 cites W2033280463 @default.
• W2778889768 cites W2037267916 @default.
• W2778889768 cites W2045157167 @default.
• W2778889768 cites W2053086049 @default.
• W2778889768 cites W2057272791 @default.
• W2778889768 cites W2066888192 @default.
• W2778889768 cites W2068180488 @default.
• W2778889768 cites W2074064091 @default.
• W2778889768 cites W2077642972 @default.
• W2778889768 cites W2078193192 @default.
• W2778889768 cites W2078801518 @default.
• W2778889768 cites W2079004374 @default.
• W2778889768 cites W2092971609 @default.
• W2778889768 cites W2093147524 @default.
• W2778889768 cites W2100592123 @default.
• W2778889768 cites W2103501749 @default.
• W2778889768 cites W2105804718 @default.
• W2778889768 cites W2106603430 @default.
• W2778889768 cites W2113534002 @default.
• W2778889768 cites W2121288523 @default.
• W2778889768 cites W2123414352 @default.
• W2778889768 cites W2125372689 @default.
• W2778889768 cites W2139996116 @default.
• W2778889768 cites W2142627514 @default.
• W2778889768 cites W2142646307 @default.
• W2778889768 cites W2143238584 @default.
• W2778889768 cites W2149658883 @default.
• W2778889768 cites W2153389501 @default.
• W2778889768 cites W2155503224 @default.
• W2778889768 cites W2162704197 @default.
• W2778889768 cites W2165395478 @default.
• W2778889768 cites W2190896638 @default.
• W2778889768 cites W2278526984 @default.
• W2778889768 cites W2281475853 @default.
• W2778889768 cites W2381339736 @default.
• W2778889768 cites W2518853827 @default.
• W2778889768 cites W2529684147 @default.
• W2778889768 cites W2530562932 @default.
• W2778889768 cites W2557803615 @default.
• W2778889768 cites W2581841075 @default.
• W2778889768 cites W2625751604 @default.
• W2778889768 doi "https://doi.org/10.18632/oncotarget.23749" @default.
• W2778889768 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5797045" @default.
• W2778889768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29435174" @default.
• W2778889768 hasPublicationYear "2017" @default.
• W2778889768 type Work @default.
• W2778889768 sameAs 2778889768 @default.
• W2778889768 citedByCount "20" @default.
• W2778889768 countsByYear W27788897682018 @default.
• W2778889768 countsByYear W27788897682019 @default.
• W2778889768 countsByYear W27788897682020 @default.
• W2778889768 countsByYear W27788897682021 @default.
• W2778889768 countsByYear W27788897682022 @default.
• W2778889768 countsByYear W27788897682023 @default.
• W2778889768 crossrefType "journal-article" @default.
• W2778889768 hasAuthorship W2778889768A5005727339 @default.
• W2778889768 hasAuthorship W2778889768A5012581623 @default.
• W2778889768 hasAuthorship W2778889768A5022710064 @default.
• W2778889768 hasAuthorship W2778889768A5024236106 @default.
• W2778889768 hasAuthorship W2778889768A5026061991 @default.
• W2778889768 hasAuthorship W2778889768A5033239597 @default.
• W2778889768 hasAuthorship W2778889768A5037677450 @default.
• W2778889768 hasAuthorship W2778889768A5039080856 @default.
• W2778889768 hasAuthorship W2778889768A5041348263 @default.
• W2778889768 hasAuthorship W2778889768A5045971373 @default.
• W2778889768 hasAuthorship W2778889768A5051013360 @default.
• W2778889768 hasAuthorship W2778889768A5055721473 @default.
• W2778889768 hasAuthorship W2778889768A5055734394 @default.

• next